Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease

High-Risk Neuroblastoma Clinical Trial

— ChIm-NB-PL  

Official title:

Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05272371
• Other study ID #: ChIm-NB-PL
• Status: Recruiting
• Phase: Phase 1
• Start date: December 1, 2021
• Est. completion date: December 31, 2026

Study information

• Verified date: March 2022
• Source: Jagiellonian University
• Contact: Walentyna Balwierz, Prof.
• Phone: +48 12 333 92 20
• Email: walentyna.balwierz[@]uj.edu.pl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Safety evaluation and initial efficacy evaluation will be conducted in a group of patients as a non-commercial, open-label clinical trial of dinutuximab beta (Qarziba) phase IIa.

The investigational medicinal product will be dinutuximab beta (anti-GD2 antibodies against GD2 disialoganglioside on NBL cells) at a dose of 10 mg / m2 / day by continuous infusion for 5 days in combination with irinotecan / temozolomide, topotecan / temozolomide or N5 / N6 chemotherapy GPOH protocol.

The study group will be patients with recurrent / progression of NBL or disease resistant to first-line treatment, for whom there are currently no standards of management, and the treatment methods used so far do not give a chance to achieve a permanent remission of the disease. After diagnosis of relapse / progression or resistance to treatment, it is permissible to administer 2 cycles of standard chemotherapy prior to enrollment in the study.

The study plans to recruit 20 patients who will receive 5-7 cycles of DB with chemotherapy. The choice of an appropriate chemotherapy regimen will depend on the patient's prior treatment and tolerance.

The safety assessment will be conducted based on the registration of the types and frequency of adverse reactions identified on the basis of the registration of clinical parameters, symptoms and / or diseases reported by the patient or identified during the intervention and / or follow-up visits, abnormal laboratory and / or imaging test results.

The initial assessment of the effectiveness will consist in comparing the percentage of objective responses obtained and the annual EFS and PFS (imaging tests, including scintigraphy, bone marrow examination and tumor markers). The study also included an exploratory evaluation of the usefulness of immunological, genetic and other studies.

Description:

Neuroblastoma (NBL) accounts for 8-10% of all childhood malignancies. It is the most common solid tumor outside the central nervous system in people <18 years of age. It occurs in 6-11 / 1 million children annually. In Poland, NBL is diagnosed annually in 60-70 patients, in 1/3 high-risk disease (HR). In 90% of children, NBL is diagnosed before the age of 5. The diagnosis is made on the basis of the histopathological assessment of the tumor tissue or the presence of NBL cells in the bone marrow together with elevated levels of catecholamines or their metabolites in the urine. The prognostic factors include the patient's age at diagnosis, stage of disease, tumor histopathology, DNA ploidy, MYCN gene status, chromosomal changes, and initial response to therapy. Due to the different course of the disease, the therapeutic decision is made after determining the risk group based on international criteria (International Neuroblastoma Risk Group Stage System, INRGSS and International Neuroblastoma Staging System, INSS). In the lowest-risk group, management is limited to observation or surgery, and in the intermediate-risk group, only standard low- and intermediate-intensity chemotherapy or combined with radiation therapy and surgery is performed. In contrast, HR-NBL uses intensive combination therapy, including standard induction chemotherapy, surgery, high-dose chemotherapy (HD-CHT) and autologous hematopoietic stem cell transplantation (auto-HSCT), radiotherapy and maintenance therapy with 13-cis retinoic acid and targeted immunotherapy with anti-GD2 antibodies. Treatment outcomes in NBL vary from spontaneous tumor regression in some infants to an OS rate of <50% despite intensive combination therapy in the HR-NBL group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 31, 2026
• Est. primary completion date: September 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 18 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of NBL according to international criteria (International Neuroblastoma Risk Group, INRG).

2. Patients 1-18 years of age with HR-NBL with primary refractory disease, disease progression or recurrence.

3. Adequate function of vital organs (if abnormal, dysfunction below grade 4 according to the CTC AE WHO classification, except for disorders defined in the exclusion criteria).

4. Life expectancy =6 months.

5. Obtaining the informed written consent of the patient and/or statutory representative for the treatment.

6. Female patients of childbearing potential must consent to the use of effective contraception; Breastfeeding patients must consent to the termination of breastfeeding.

7. Patients who have previously received immunotherapy with DB or other anti-GD2 specific antibodies may be eligible for this study.

Exclusion Criteria:

1. Patients with toxicities of =3 CTCAE WHO grade, except hearing impairment, hematological disorders, liver and kidney disorders.

2. Patients with neurological toxicities of =2 CTCAE WHO grade.

3. Active life-threatening infection until stabilization of the patient's condition.

4. Pregnancy and / or lactation.

5. Sexually active patients who refuse to use an effective method of contraception.

6. Current treatment with experimental drugs or use of such treatment within 2 weeks before signing the informed consent to participate in the study.

7. Radiotherapy within 3 weeks prior to the start of the study.

8. Participation in another clinical trial within 6 months before signing the informed consent to participate in the trial (not applicable to clinical trials in 1st line of treatment in HR-NBL).

9. Lack of informed written consent to treatment.

Related Conditions & MeSH terms

• Disease Progression
• High-Risk Neuroblastoma
• Neuroblastoma

Intervention

Combination Product:
• Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)
Dinutuximab beta in combination with chemotherapy.

Locations

Country	Name	City	State
Poland	University Children Hospital	Krakow	Malopolska

Sponsors (1)

Lead Sponsor	Collaborator
Jagiellonian University

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of cycles aborted due to toxicity.		12 months after end of treatment.
Primary	Number of cycles in which treatment interruptions due to the occurrence of side effects will be longer than provided for in the treatment protocol.		12 months after end of treatment.
Primary	Number of episodes of Capillary Leak Syndrome, regardless of severity.		12 months after end of treatment.
Primary	Number of episodes of cytokine release syndrome, regardless of severity.		12 months after end of treatment.
Primary	Number of episodes of allergic reactions in CTCAE grade 3 and 4 (version in force at that time).		12 months after end of treatment.
Primary	Number of hematological toxicities in grade 3 and 4 CTCAE (version in force at that time).		12 months after end of treatment.
Primary	Number of neurological toxicity episodes, regardless of severity.		12 months after end of treatment.
Primary	The percentage of patients with pupil disorders and / or visual disturbances.		12 months after end of treatment.
Primary	Proportion of patients with renal or hepatic impairment in CTCAE grade 3 and 4 (version in force at that time).		12 months after end of treatment.
Primary	Other side effects in grade 3 and 4 CTCAE (version in force at the time)3 and 4 (version in force at that time).		12 months after end of treatment.
Secondary	Percentage of patients with complete remission assessed during the study and at the last visit.		12 months after end of treatment.
Secondary	Percentage of patients with partial remission assessed during the study and at the last visit.		12 months after end of treatment.
Secondary	Percentage of patients with disease stabilization assessed during the examination and at the last visit.		12 months after end of treatment.
Secondary	Percentage of patients PFS assessed during the study.		12 months after end of treatment.
Secondary	Percentage of patients ESF assessed during the study.		12 months after end of treatment.